Merck's Keytruda Wins Eighth FDA Approval Of 2021, This Time For Adjuvant, Pediatric Melanoma SettingsBenzinga • 12/06/21
FDA Approves Merck's KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete ResectionBusiness Wire • 12/03/21
Merck to supply Government of Canada with up to 1 million courses molnupiravir, its COVID-19 pillMarket Watch • 12/03/21
Merck & Co., Inc. (MRK) Management on 4th Annual Evercore ISI HealthCONx Virtual Conference (Transcript)Seeking Alpha • 12/01/21
After high hopes for Merck's COVID-19 pill, Wall Street now expects a ‘tepid' authorizationMarket Watch • 12/01/21
Merck's Pneumococcal 15-valent Conjugate Vaccine Under Priority FDA Review For Use In KidsBenzinga • 12/01/21
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Merck's VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and ChildrenBusiness Wire • 12/01/21